CSLC0501

INTERVENTION: Patients with operable stage IB to IIIA NSCLC were randomised either to radical resection followed by three cycles of TP (Arm A) or three cycles of TP followed by radical resection (Arm B). Arm A: post‐operative chemotherapy(adjuvant) Arm B: pre‐operative chemotherapy(neo‐adjuvant)TP regimen: Docetaxel: 75 mg/m², day 1 intravenous for1 hour, Carboplatin : AUC 5 , day 1 intravenous for 1 hour, Treatment is repeated every 3 weeks for a total of 3 cycles. All randomised patients who do not receive resection will be recommended to receive relevant treatment in line with National Comprehensive Cancer Network (NCCN) guideline. CONDITION: Non‐small cell lung cancer PRIMARY OUTCOME: 3 years Disease Free Survival SECONDARY OUTCOME: 3 years Overall Survival rate Safety data INCLUSION CRITERIA: Histologically or cytologically confirmed stage IB‐IIIA non‐small cell lung cancer patients,without previous chemotherapy, radiotherapy or target‐therapy; PS with ECOC 0‐1; Adequate haematological and Hepatic‐ renal function; Expected live longer than 12monthes; The informed consent should be signed.